Group 1: Company Overview and Market Position - The company is recognized as one of the earliest domestic enterprises in China to develop and manufacture medical monitoring devices, designated as a "National Multi-parameter Monitoring Instrument Industrialization Base" by the National Development and Reform Commission [1] - The company positions itself as a "critical care pioneer," focusing on high-end monitoring equipment primarily for ICU, anesthesia, and operating rooms, emphasizing high prices, added value, and technical barriers [1] - The P series plug-in monitor has won the "Red Dot Award" and features industry-leading anti-electrosurgical interference technology, intelligent early warning, high-end parameter integration analysis, and smart voice assistance [1] Group 2: Product Development and Innovation - The company plans to continue focusing on clinical needs, leveraging over 30 years of industry experience to enhance technological innovation and integrate smart solutions into product development [2] - New products will address core clinical pain points and feature "new quality" attributes, transitioning medical devices from "functional integration" to "intelligent decision-making" [2] Group 3: International Sales and Market Expansion - The company's blood dialysis products have entered overseas markets, with a 121.29% increase in overseas blood dialysis revenue in the first half of 2025, indicating positive growth [3] - The company aims to actively seize opportunities to expand its overseas blood dialysis market presence [3] Group 4: Regulatory Impact and Market Growth - The National Healthcare Security Administration's new pricing guidelines for blood dialysis services include monitoring items such as blood temperature and blood pressure, which the company's D800 series dialysis equipment can meet without additional modules [4] - The blood dialysis market has maintained a stable annual compound growth rate of approximately 12% over the past decade, with 1.027 million patients undergoing dialysis in 2024 [5] - The domestic blood dialysis equipment market saw sales growth in the first three quarters of 2025, driven by hospital operational recovery and centralized procurement [6] Group 5: New Product Launches and Financial Performance - Recent product launches include peritoneal dialysis machines, S series infusion pumps, electronic urine measuring devices, and telemetry monitors, enhancing the life information and support product line [6] - The subsidiary Suzhou Junkang reported revenue of 74.146 million yuan in the first three quarters of 2025, with plans to increase new product development and market expansion efforts [6]

证券代码：300246 证券简称：宝莱特 公告编号：2025-074 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 关于"宝莱转债"回售的第二次提示性公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 8、"宝莱转债"持有人有权选择是否进行回售，本次回售不具有强制性 9、风险提示：持有人本次选择回售等同于以 100.527 元/张（含息税）的价 格卖出持有的"宝莱转债"。截至目前，"宝莱转债"的收盘价格高于本次回售价 格，投资者选择回售可能带来损失，敬请投资者注意风险。 特别提示： 1、回售价格：100.527 元/张（含息税） 2、回售条件满足日：2025 年 10 月 23 日 3、回售申报期：2025 年 10 月 29 日至 2025 年 11 月 4 日 4、发行人资金到账日：2025 年 11 月 7 日 5、回售款划拨日：2025 年 11 月 10 日 6、投资者回售款到账日：2025 年 11 月 11 日 7、回售期内暂停转股 广东宝莱特医用科技股份有限公司（以下简称"公司"）的股票自 2025 年 9 月 4 ...

证券代码：300246 证券简称：宝莱特 公告编号：2025-073 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 关于"宝莱转债"回售的第一次提示性公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、回售价格：100.527 元/张（含息税） 2、回售条件满足日：2025 年 10 月 23 日 3、回售申报期：2025 年 10 月 29 日至 2025 年 11 月 4 日 4、发行人资金到账日：2025 年 11 月 7 日 5、回售款划拨日：2025 年 11 月 10 日 6、投资者回售款到账日：2025 年 11 月 11 日 7、回售期内暂停转股 8、"宝莱转债"持有人有权选择是否进行回售，本次回售不具有强制性 9、风险提示：持有人本次选择回售等同于以 100.527 元/张（含息税）的价 格卖出持有的"宝莱转债"。截至目前，"宝莱转债"的收盘价格高于本次回售价 格，投资者选择回售可能带来损失，敬请投资者注意风险。 广东宝莱特医用科技股份有限公司（以下简称"公司"）的股票自 2025 年 9 月 4 ...

Core Insights - Baolait's Q3 2023 performance shows a decline in revenue and net profit, with a total revenue of 7.93 billion yuan for the first three quarters, down 1.77% year-on-year, and a net loss of 8.34 million yuan, although the loss has narrowed compared to previous periods [1][2] Financial Performance - In Q3 2023, the company's revenue was 2.7 billion yuan, a decrease of 0.5% year-on-year, with a net loss of 9.66 million yuan, improving from a loss of 11.13 million yuan in the same period last year [1] - For the first three quarters, the gross profit margin fell from 27.18% to 25.31%, with projected gross profit margins of 32.43% and 27.12% for 2023 and 2024 respectively, indicating a continuous decline [1] Company Overview - Baolait specializes in the research, production, and sales of medical monitoring devices, primarily multi-parameter monitors, including handheld monitors, integrated monitors, and plug-in monitors [2] - The company's revenue from 2021 to 2024 shows a downward trend, with figures of 10.91 billion yuan, 11.84 billion yuan, 11.94 billion yuan, and 10.60 billion yuan, reflecting a significant revenue pressure [2] Debt and Guarantees - As of the announcement date, the company has provided guarantees totaling 400 million yuan for its subsidiaries, which represents 32.82% of the latest audited net assets and 16.01% of the latest audited total assets [2]

Core Viewpoint - Baolait (300246.SZ) reported a decline in revenue and a net loss for the first three quarters of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for the first three quarters was 793 million yuan, representing a year-on-year decrease of 1.77% [1] - The net loss attributable to shareholders of the listed company was 8.34 million yuan [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 29.14 million yuan [1] - The basic loss per share was 0.0315 yuan [1]

Group 1 - Company Baolait reported a revenue of approximately 793 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 1.77% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 8.34 million yuan, with a basic earnings per share loss of 0.0315 yuan [1] - As of the report date, Baolait's market capitalization stood at 2.3 billion yuan [2] Group 2 - The Chinese innovative drug sector has seen overseas licensing sales reach 80 billion US dollars this year [2] - The secondary market for biomedicine is experiencing a surge, while the primary market is facing challenges in fundraising [2]

Group 1 - The company Baolait (SZ 300246) announced that as of the date of the announcement, the total amount of external guarantees provided by the company reached 400 million yuan, accounting for 32.82% of the company's most recent audited net assets and 16.01% of the company's most recent audited total assets, all of which are guarantees for subsidiaries [1] - For the year 2024, the revenue composition of Baolait is as follows: medical devices account for 69.34%, commercial activities account for 29.46%, and other businesses account for 1.2% [1] - As of the time of reporting, Baolait's market capitalization is 2.3 billion yuan [1]

证券代码：300246 证券简称：宝莱特 公告编号：2025-070 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 关于公司为子公司提供担保的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 一、担保概况 广东宝莱特医用科技股份有限公司（以下简称"公司"）于 2025 年 10 月 24 日召开了第九届董事会第四次会议，审议通过了《关于为子公司苏州君康提供担 保的议案》，为保证公司子公司苏州君康医疗科技有限公司（以下简称"苏州君 康"）生产经营的资金需求，公司董事会同意苏州君康在苏州银行科技城支行申 请授信额度为 15,000 万元，公司为上述融资提供全额的连带责任担保，在额度 内可循环使用，担保期限为自本次董事会决议生效日起至 2029 年 12 月 31 日止。 具体审批额度及担保期限依据苏州君康与银行等机构最终协商后签署的担保合 同为准。 根据《深圳证券交易所创业板股票上市规则》、《公司章程》等相关规定， 本次担保金额占公司最近一期经审计净资产的 12.31%，本议案尚需提交公司 2025 年第四次临时股东会审议。董事会授权 ...

证券代码：300246 证券简称：宝莱特 公告编号：2025-072 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 关于召开 2025 年第四次临时股东会的通知 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第四次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》 等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 10 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 10 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的 具体时间为 2025 年 11 月 10 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络 ...

证券代码：300246 证券简称：宝莱特 公告编号：2025-068 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 第九届董事会第四次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 广东宝莱特医用科技股份有限公司（以下简称"公司"）于 2025 年 10 月 24 日以通讯表决及现场会议相结合的方式召开第九届董事会第四次会议，会议 通知于 2025 年 10 月 21 日以电子邮件、电话及传真方式送达，公司董事会共有 董事九名，参与表决的董事共九名，符合《公司法》和《公司章程》的规定。 会议由公司董事长燕金元先生主持，经逐项表决，审议通过了以下议案： 一、 审议通过了公司《2025 年第三季度报告》的议案 全体董事一致认为，公司《2025 年第三季度报告》的编制过程、内容、格 式符合相关文件的规定；定期报告编制期间，未有泄密及其他违反法律法规、《公 司章程》或损害公司利益的行为发生；公司财务报告真实、准确、完整地反映了 公司的财务状况和经营状况，不存在任何虚假记载、误导性陈述或者重大遗漏。 本议案已经公司审计委员会审议通 ...